Adenovirus Vectors Expressing Hantavirus Proteins Protect Hamsters against Lethal Challenge with Andes Virus
- 15 July 2009
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 83 (14) , 7285-7295
- https://doi.org/10.1128/jvi.00373-09
Abstract
Hantaviruses infect humans following aerosolization from rodent feces and urine, producing hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Due to the high rates of mortality and lack of therapies, vaccines are urgently needed. Nonreplicating adenovirus (Ad) vectors that express Andes hantavirus (ANDV) nucleocapsid protein (AdN) or glycoproteins (AdG N and AdG C ) were constructed. Ad vectors were tested for their ability to protect Syrian hamsters from a lethal ANDV infection that mimics the pulmonary disease seen in humans. When administered once, all three Ad vectors, individually or in combination, elicited a robust immune response that protected hamsters. No vaccinated animal died, and there were no obvious clinical signs of disease. Further, hantavirus RNA was not detected by sensitive reverse transcription-PCR in tissues and blood of hamsters immunized with both AdG N and AdG C . Cellular immunity appeared to be important for protection because the AdN vector completely protected animals. All three Ad vectors produced strong cytotoxic T-lymphocyte responses directed to hantavirus proteins in mice. Moreover, hamsters vaccinated with AdN, AdG N , or AdG C produced no detectable neutralizing antibodies yet were protected. These Ad vectors represent the first vaccines that prevent lethal hantavirus disease and, in some instances (AdG N and AdG C ), provide sterile immunity. These observations set the stage for a more detailed characterization of the types of immunity required to protect humans from hantavirus infections.Keywords
This publication has 62 references indexed in Scilit:
- Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in MicePLOS ONE, 2008
- Hantavirus‐induced immunity in rodent reservoirs and humansImmunological Reviews, 2008
- Single-Dose Protection againstPlasmodium bergheiby a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron AJournal of Virology, 2008
- Immune Serum Produced by DNA Vaccination Protects Hamsters against Lethal Respiratory Challenge with Andes VirusJournal of Virology, 2008
- Characterization of the Human Cytomegalovirus gH/gL/UL128-131 Complex That Mediates Entry into Epithelial and Endothelial CellsJournal of Virology, 2008
- Treatment of hantavirus pulmonary syndromeAntiviral Research, 2007
- Hantaviruses: Immunology, Treatment, and PreventionViral Immunology, 2004
- Placebo-Controlled, Double-Blind Trial of Intravenous Ribavirin for the Treatment of Hantavirus Cardiopulmonary Syndrome in North AmericaClinical Infectious Diseases, 2004
- Use of Vesicular Stomatitis Virus Pseudotypes Bearing Hantaan or Seoul Virus Envelope Proteins in a Rapid and Safe Neutralization TestClinical and Vaccine Immunology, 2003
- Utilization of autopsy RNA for the synthesis of the nucleocapsid antigen of a newly recognized virus associated with hantavirus pulmonary syndromeVirus Research, 1993